(Q38093053)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

A systematic review of utility values for chemotherapy-related adverse events (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Rachel A. Elliott

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Katherine Payne

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Fatiha H Shabaruddin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

1 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

277-288

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40273-013-0033-x

27 February 2020

exact match

0 references

cites work

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Valuing health-related quality of life. A review of health state valuation techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Preference values associated with stage III colon cancer and adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Societal preference values for advanced melanoma health states in the United Kingdom and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Cost effectiveness of treatment options in advanced breast cancer in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Are health states 'timeless'? A case study of an acute condition: post-chemotherapy nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Health state utilities for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Health state utility scores for cancer-related anemia through societal and patient valuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Health utility scores of colorectal cancer based on societal preference in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

An updated systematic review of Health State Utility Values for osteoporosis related conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

One thousand health-related quality-of-life estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Health utility elicitation: is there still a role for direct methods?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Methods for measuring temporary health States for cost-utility analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Utilities should not be multiplied: evidence from the preference-based scores in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0033-X

Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis

21 January 2018

1 reference

12 December 2020

Utility valuations for outcome states of colorectal cancer

1 reference

12 December 2020

Are adverse effects incorporated in economic models? An initial review of current practice

1 reference

12 December 2020

Health state utilities for non small cell lung cancer

1 reference

12 December 2020

Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study

1 reference

12 December 2020

Adverse drug reactions: types and treatment options

1 reference

12 December 2020

10.1007/S40273-013-0033-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json

release_fslu4rr3bbblljfgggvz4fqdfm

27 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fslu4rr3bbblljfgggvz4fqdfm

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529208%20AND%20SRC:MED&resulttype=core&format=json